You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNimesulide
Accession NumberDB04743
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionNimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AinexNot Available
AulinNot Available
CoxtalNot Available
EskaflamNot Available
Mesulid Not Available
NilsidNot Available
NimaloxNot Available
NimsideNot Available
NiseNot Available
OctaprinNot Available
SintalginNot Available
SulideNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIV4TKW1454M
CAS number51803-78-2
WeightAverage: 308.31
Monoisotopic: 308.046692194
Chemical FormulaC13H12N2O5S
InChI KeyInChIKey=HYWYRSMBCFDLJT-UHFFFAOYSA-N
InChI
InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3
IUPAC Name
N-(4-nitro-2-phenoxyphenyl)methanesulfonamide
SMILES
CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylethers
Direct ParentDiphenylethers
Alternative Parents
Substituents
  • Diphenylether
  • Diaryl ether
  • Sulfanilide
  • Nitrobenzene
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Ether
  • Hydrocarbon derivative
  • Organic salt
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organic zwitterion
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.
PharmacodynamicsFood, gender and advanced age have negligible effects on nimesulide pharmacokinetics.
Mechanism of actionThe therapeutic effects of Nimesulide are the result of its complete mode of action which targets a number of key mediators of the inflammatory process such as: COX-2 mediated prostaglandins, free radicals, proteolytic enzymes and histamine.
Related Articles
AbsorptionRapidly absorbed following oral administration.
Volume of distributionNot Available
Protein binding>97.5%
Metabolism

Hepatic. Extensive biotransformation, mainly to 4-hydroxynimesulide (which also appears to be biologically active).

Route of eliminationRenal (50%), fecal (29%)
Half life1.8–4.7 hours
ClearanceNot Available
ToxicityOral TDLO (human): 1.429 mg/kg; Oral TDLO (woman): 2 mg/kg; Oral LD50 (rat): 200 mg/kg; Oral LD50 (mouse): 392 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.6341
Caco-2 permeable-0.55
P-glycoprotein substrateNon-substrate0.8267
P-glycoprotein inhibitor INon-inhibitor0.5634
P-glycoprotein inhibitor IINon-inhibitor0.8129
Renal organic cation transporterNon-inhibitor0.8943
CYP450 2C9 substrateNon-substrate0.6235
CYP450 2D6 substrateNon-substrate0.8055
CYP450 3A4 substrateSubstrate0.5257
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.7628
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8952
Ames testAMES toxic0.6488
CarcinogenicityNon-carcinogens0.6116
BiodegradationNot ready biodegradable0.9901
Rat acute toxicity3.0832 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5345
hERG inhibition (predictor II)Non-inhibitor0.5574
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point143-144.5 °CPhysProp
logP2.60SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0182 mg/mLALOGPS
logP2.56ALOGPS
logP1.79ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)6.86ChemAxon
pKa (Strongest Basic)-8.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area101.22 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity76.31 m3·mol-1ChemAxon
Polarizability28.87 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Bernard Pirotte, Geraldine Piel, Philippe Neven, Isabelle Delneuville, Joszef Geczy, “Water-soluble nimesulide salt and its preparation, aqueous dolution containing it, nimesulide-based combinations and their uses.” U.S. Patent US5756546, issued November, 1991.

US5756546
General ReferencesNot Available
External Links
ATC CodesM02AA26M01AX17
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (23.5 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nimesulide.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nimesulide.
AbciximabNimesulide may increase the anticoagulant activities of Abciximab.
AbciximabAbciximab may increase the antiplatelet activities of Nimesulide.
AcebutololNimesulide may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aceclofenac.
AcenocoumarolNimesulide may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Nimesulide.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Nimesulide.
Alendronic acidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alendronic acid.
AlfuzosinAlfuzosin may increase the hypotensive activities of Nimesulide.
AliskirenNimesulide may decrease the antihypertensive activities of Aliskiren.
AlprenololNimesulide may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Nimesulide.
AlprostadilAlprostadil may increase the antiplatelet activities of Nimesulide.
AlteplaseNimesulide may increase the anticoagulant activities of Alteplase.
ALX-0081Nimesulide may increase the anticoagulant activities of ALX-0081.
AmikacinNimesulide may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideNimesulide may decrease the antihypertensive activities of Amiloride.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aminosalicylic Acid.
AmobarbitalThe metabolism of Nimesulide can be increased when combined with Amobarbital.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nimesulide.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nimesulide.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nimesulide.
AnagrelideNimesulide may increase the anticoagulant activities of Anagrelide.
AnagrelideAnagrelide may increase the antiplatelet activities of Nimesulide.
AncrodNimesulide may increase the anticoagulant activities of Ancrod.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nimesulide.
AnistreplaseNimesulide may increase the anticoagulant activities of Anistreplase.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nimesulide.
Antithrombin III humanNimesulide may increase the anticoagulant activities of Antithrombin III human.
ApixabanNimesulide may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Nimesulide is combined with Apremilast.
ArdeparinNimesulide may increase the anticoagulant activities of Ardeparin.
ArgatrobanNimesulide may increase the anticoagulant activities of Argatroban.
ArgatrobanArgatroban may increase the antiplatelet activities of Nimesulide.
ArotinololNimesulide may decrease the antihypertensive activities of Arotinolol.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Nimesulide.
AstaxanthinNimesulide may increase the anticoagulant activities of Astaxanthin.
AtenololNimesulide may decrease the antihypertensive activities of Atenolol.
AtosibanThe risk or severity of adverse effects can be increased when Nimesulide is combined with Atosiban.
Atracurium besylateNimesulide may increase the neuromuscular blocking activities of Atracurium besylate.
AzapropazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nimesulide.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nimesulide.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nimesulide.
BalsalazideNimesulide may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Nimesulide.
BarbitalThe metabolism of Nimesulide can be increased when combined with Barbital.
BatroxobinNimesulide may increase the anticoagulant activities of Batroxobin.
BecaplerminNimesulide may increase the anticoagulant activities of Becaplermin.
BefunololNimesulide may decrease the antihypertensive activities of Befunolol.
BemiparinNimesulide may increase the anticoagulant activities of Bemiparin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nimesulide.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nimesulide.
BenoxaprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Benoxaprofen.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nimesulide.
BeraprostNimesulide may increase the anticoagulant activities of Beraprost.
BeraprostBeraprost may increase the antiplatelet activities of Nimesulide.
BetaxololNimesulide may decrease the antihypertensive activities of Betaxolol.
BevantololNimesulide may decrease the antihypertensive activities of Bevantolol.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nimesulide.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nimesulide.
BisoprololNimesulide may decrease the antihypertensive activities of Bisoprolol.
BivalirudinNimesulide may increase the anticoagulant activities of Bivalirudin.
BopindololNimesulide may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nimesulide.
BufuralolNimesulide may decrease the antihypertensive activities of Bufuralol.
BumetanideNimesulide may decrease the diuretic activities of Bumetanide.
BupranololNimesulide may decrease the antihypertensive activities of Bupranolol.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nimesulide.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nimesulide.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nimesulide.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nimesulide.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nimesulide.
CangrelorNimesulide may increase the anticoagulant activities of Cangrelor.
CangrelorCangrelor may increase the antiplatelet activities of Nimesulide.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nimesulide.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nimesulide.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Nimesulide.
CarteololNimesulide may decrease the antihypertensive activities of Carteolol.
CarvedilolNimesulide may decrease the antihypertensive activities of Carvedilol.
CarvedilolCarvedilol may increase the hypotensive activities of Nimesulide.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nimesulide.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nimesulide.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Nimesulide.
CeliprololNimesulide may decrease the antihypertensive activities of Celiprolol.
CertoparinNimesulide may increase the anticoagulant activities of Certoparin.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nimesulide.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nimesulide.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nimesulide.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nimesulide.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nimesulide.
CholestyramineCholestyramine can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nimesulide.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nimesulide.
CilostazolNimesulide may increase the anticoagulant activities of Cilostazol.
CilostazolCilostazol may increase the antiplatelet activities of Nimesulide.
CimetidineThe serum concentration of Nimesulide can be increased when it is combined with Cimetidine.
Citric AcidNimesulide may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clonixin.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimesulide.
ClopidogrelClopidogrel may increase the antiplatelet activities of Nimesulide.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Nimesulide.
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Nimesulide.
ColesevelamColesevelam can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CollagenaseThe risk or severity of adverse effects can be increased when Nimesulide is combined with Collagenase.
CyclosporineNimesulide may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nimesulide.
D-LimoneneThe risk or severity of adverse effects can be increased when Nimesulide is combined with D-Limonene.
Dabigatran etexilateNimesulide may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinNimesulide may increase the anticoagulant activities of Dalteparin.
DanaparoidNimesulide may increase the anticoagulant activities of Danaparoid.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nimesulide.
DasatinibDasatinib may increase the anticoagulant activities of Nimesulide.
DaunorubicinNimesulide may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nimesulide.
DeferasiroxThe risk or severity of adverse effects can be increased when Nimesulide is combined with Deferasirox.
DefibrotideNimesulide may increase the anticoagulant activities of Defibrotide.
DefibrotideDefibrotide may increase the antiplatelet activities of Nimesulide.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Deoxycholic Acid.
DesirudinNimesulide may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desmopressin.
DesmoteplaseNimesulide may increase the anticoagulant activities of Desmoteplase.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nimesulide.
DextranNimesulide may increase the anticoagulant activities of Dextran.
Dextran 40Nimesulide may increase the anticoagulant activities of Dextran 40.
Dextran 70Nimesulide may increase the anticoagulant activities of Dextran 70.
Dextran 75Nimesulide may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nimesulide.
DicoumarolNimesulide may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Nimesulide.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nimesulide.
DihydrostreptomycinNimesulide may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nimesulide.
DipyridamoleNimesulide may increase the anticoagulant activities of Dipyridamole.
DipyridamoleDipyridamole may increase the antiplatelet activities of Nimesulide.
DitazoleNimesulide may increase the anticoagulant activities of Ditazole.
DoxazosinDoxazosin may increase the hypotensive activities of Nimesulide.
DoxorubicinNimesulide may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneNimesulide may increase the hyperkalemic activities of Drospirenone.
Drotrecogin alfaNimesulide may increase the anticoagulant activities of Drotrecogin alfa.
DroxicamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Droxicam.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nimesulide.
Edetic AcidNimesulide may increase the anticoagulant activities of Edetic Acid.
EdoxabanNimesulide may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Nimesulide can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nimesulide.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nimesulide.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nimesulide.
EnoxaparinNimesulide may increase the anticoagulant activities of Enoxaparin.
EpinastineEpinastine may increase the antiplatelet activities of Nimesulide.
EpirizoleThe risk or severity of adverse effects can be increased when Nimesulide is combined with Epirizole.
EpirubicinNimesulide may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneNimesulide may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nimesulide.
EpoprostenolEpoprostenol may increase the antiplatelet activities of Nimesulide.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nimesulide.
EptifibatideNimesulide may increase the anticoagulant activities of Eptifibatide.
EptifibatideEptifibatide may increase the antiplatelet activities of Nimesulide.
EsmololNimesulide may decrease the antihypertensive activities of Esmolol.
Etacrynic acidNimesulide may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Nimesulide.
Ethyl biscoumacetateNimesulide may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Nimesulide.
EtofenamateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Nimesulide.
Evening primrose oilThe risk or severity of adverse effects can be increased when Nimesulide is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Nimesulide is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nimesulide.
FibrinolysinNimesulide may increase the anticoagulant activities of Fibrinolysin.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nimesulide.
FluconazoleThe serum concentration of Nimesulide can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nimesulide.
FlunixinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nimesulide.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nimesulide.
Fondaparinux sodiumNimesulide may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Nimesulide.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nimesulide.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nimesulide.
FramycetinNimesulide may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideNimesulide may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Nimesulide.
GentamicinNimesulide may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GlucosamineGlucosamine may increase the antiplatelet activities of Nimesulide.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nimesulide.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nimesulide.
HaloperidolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Haloperidol.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nimesulide.
HeparinNimesulide may increase the anticoagulant activities of Heparin.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nimesulide.
HexobarbitalThe metabolism of Nimesulide can be increased when combined with Hexobarbital.
HirulogNimesulide may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Nimesulide is combined with HMPL-004.
HydralazineNimesulide may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nimesulide.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nimesulide.
Hygromycin BNimesulide may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibandronate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nimesulide.
IbudilastNimesulide may increase the antiplatelet activities of Ibudilast.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nimesulide.
IbuproxamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Nimesulide is combined with Icatibant.
Icosapent ethylNimesulide may increase the antiplatelet activities of Icosapent ethyl.
IdarubicinNimesulide may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IfenprodilNimesulide may increase the antiplatelet activities of Ifenprodil.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nimesulide.
IloprostIloprost may increase the antiplatelet activities of Nimesulide.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nimesulide.
IndenololNimesulide may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nimesulide.
IndoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Indoprofen.
IndoraminIndoramin may increase the hypotensive activities of Nimesulide.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nimesulide.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nimesulide.
IsoxicamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Isoxicam.
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Nimesulide.
KanamycinNimesulide may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Kebuzone.
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Nimesulide.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nimesulide.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nimesulide.
LabetalolNimesulide may decrease the antihypertensive activities of Labetalol.
LabetalolLabetalol may increase the hypotensive activities of Nimesulide.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Nimesulide.
LepirudinNimesulide may increase the anticoagulant activities of Lepirudin.
LevobunololNimesulide may decrease the antihypertensive activities of Levobunolol.
LimaprostLimaprost may increase the antiplatelet activities of Nimesulide.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nimesulide.
LithiumThe serum concentration of Lithium can be increased when it is combined with Nimesulide.
LornoxicamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nimesulide.
LoxoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nimesulide.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Nimesulide.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nimesulide.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Magnesium Sulfate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nimesulide.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nimesulide.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nimesulide.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nimesulide.
MesalazineNimesulide may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Nimesulide.
MetamizoleThe risk or severity of adverse effects can be increased when Nimesulide is combined with Metamizole.
MethohexitalThe metabolism of Nimesulide can be increased when combined with Methohexital.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nimesulide.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nimesulide.
MethylphenobarbitalThe metabolism of Nimesulide can be increased when combined with Methylphenobarbital.
MetipranololNimesulide may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nimesulide.
MetoprololNimesulide may decrease the antihypertensive activities of Metoprolol.
MetrizamideNimesulide may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nimesulide.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nimesulide.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nimesulide.
MilrinoneMilrinone may increase the antiplatelet activities of Nimesulide.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nimesulide.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nimesulide.
MivacuriumNimesulide may increase the neuromuscular blocking activities of Mivacurium.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nimesulide.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nimesulide.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nimesulide.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nimesulide.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nimesulide.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nimesulide.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Nimesulide.
NadololNimesulide may decrease the antihypertensive activities of Nadolol.
NadroparinNimesulide may increase the anticoagulant activities of Nadroparin.
NafcillinThe metabolism of Nimesulide can be increased when combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nimesulide.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Nimesulide.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nimesulide.
NCX 4016The risk or severity of adverse effects can be increased when Nimesulide is combined with NCX 4016.
NeomycinNimesulide may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Nepafenac.
NetilmicinNimesulide may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nimesulide.
NitroprussideNimesulide may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nimesulide.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nimesulide.
ObinutuzumabThe risk or severity of adverse effects can be increased when Nimesulide is combined with Obinutuzumab.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nimesulide.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nimesulide.
OlsalazineNimesulide may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nimesulide.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Nimesulide.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Nimesulide.
OrgoteinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Orgotein.
OtamixabanNimesulide may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nimesulide.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nimesulide.
OxprenololNimesulide may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nimesulide.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nimesulide.
PamidronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Parecoxib.
ParnaparinNimesulide may increase the anticoagulant activities of Parnaparin.
ParomomycinNimesulide may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololNimesulide may decrease the antihypertensive activities of Penbutolol.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nimesulide.
PentobarbitalThe metabolism of Nimesulide can be increased when combined with Pentobarbital.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nimesulide.
Pentosan PolysulfateNimesulide may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Nimesulide.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nimesulide.
PhenindioneNimesulide may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Nimesulide can be increased when combined with Phenobarbital.
PhenprocoumonNimesulide may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nimesulide.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nimesulide.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nimesulide.
PindololNimesulide may decrease the antihypertensive activities of Pindolol.
PiretanideNimesulide may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nimesulide.
PlasminNimesulide may increase the anticoagulant activities of Plasmin.
PlicamycinNimesulide may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nimesulide.
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Nimesulide.
PractololNimesulide may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Nimesulide.
PrasugrelNimesulide may increase the anticoagulant activities of Prasugrel.
PrasugrelPrasugrel may increase the antiplatelet activities of Nimesulide.
PrazosinPrazosin may increase the hypotensive activities of Nimesulide.
PrimidoneThe metabolism of Nimesulide can be increased when combined with Primidone.
ProbenecidThe serum concentration of Nimesulide can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Propacetamol.
PropranololNimesulide may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Nimesulide.
Protein CNimesulide may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeNimesulide may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Nimesulide is combined with PTC299.
PuromycinNimesulide may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nimesulide.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nimesulide.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nimesulide.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nimesulide.
RapacuroniumNimesulide may increase the neuromuscular blocking activities of Rapacuronium.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nimesulide.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nimesulide.
ReteplaseNimesulide may increase the anticoagulant activities of Reteplase.
ReviparinNimesulide may increase the anticoagulant activities of Reviparin.
RibostamycinNimesulide may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RidogrelRidogrel may increase the antiplatelet activities of Nimesulide.
RisedronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Risedronate.
RivaroxabanNimesulide may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Nimesulide.
RosiglitazoneNimesulide may increase the anticoagulant activities of Rosiglitazone.
SalicylamideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Salicylamide.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nimesulide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nimesulide.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Nimesulide.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nimesulide.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Nimesulide.
SCH-530348Nimesulide may increase the antiplatelet activities of SCH-530348.
SecobarbitalThe metabolism of Nimesulide can be increased when combined with Secobarbital.
SelexipagNimesulide may increase the anticoagulant activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Nimesulide is combined with Seratrodast.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nimesulide.
SevofluraneSevoflurane may increase the antiplatelet activities of Nimesulide.
SilodosinSilodosin may increase the hypotensive activities of Nimesulide.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nimesulide.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nimesulide.
SotalolNimesulide may decrease the antihypertensive activities of Sotalol.
SpectinomycinNimesulide may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Nimesulide.
SpironolactoneNimesulide may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Nimesulide is combined with SRT501.
StreptokinaseNimesulide may increase the anticoagulant activities of Streptokinase.
StreptomycinNimesulide may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinNimesulide may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nimesulide.
SulfasalazineNimesulide may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nimesulide.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Nimesulide.
SulodexideNimesulide may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Nimesulide.
TacrolimusNimesulide may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Nimesulide.
TamsulosinTamsulosin may increase the hypotensive activities of Nimesulide.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nimesulide.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nimesulide.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nimesulide.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Nimesulide.
TenecteplaseNimesulide may increase the anticoagulant activities of Tenecteplase.
TenofovirThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nimesulide.
TepoxalinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tepoxalin.
TerazosinTerazosin may increase the hypotensive activities of Nimesulide.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nimesulide.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nimesulide.
TeriflunomideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Teriflunomide.
TesmilifeneNimesulide may increase the antiplatelet activities of Tesmilifene.
ThiamylalThe metabolism of Nimesulide can be increased when combined with Thiamylal.
ThiopentalThe metabolism of Nimesulide can be increased when combined with Thiopental.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nimesulide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nimesulide.
TicagrelorNimesulide may increase the anticoagulant activities of Ticagrelor.
TiclopidineNimesulide may increase the anticoagulant activities of Ticlopidine.
TiclopidineTiclopidine may increase the antiplatelet activities of Nimesulide.
TiludronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tiludronate.
TimololNimesulide may decrease the antihypertensive activities of Timolol.
TinzaparinNimesulide may increase the anticoagulant activities of Tinzaparin.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nimesulide.
TipranavirTipranavir may increase the antiplatelet activities of Nimesulide.
TirofibanNimesulide may increase the anticoagulant activities of Tirofiban.
TirofibanTirofiban may increase the antiplatelet activities of Nimesulide.
TobramycinNimesulide may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nimesulide.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nimesulide.
TorasemideNimesulide may decrease the diuretic activities of Torasemide.
TositumomabThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tositumomab.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nimesulide.
TranilastThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tranilast.
TrapidilNimesulide may increase the antiplatelet activities of Trapidil.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nimesulide.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nimesulide.
TreprostinilNimesulide may increase the anticoagulant activities of Treprostinil.
TriamtereneNimesulide may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nimesulide.
TriflusalNimesulide may increase the anticoagulant activities of Triflusal.
TriflusalTriflusal may increase the antiplatelet activities of Nimesulide.
TrimazosinTrimazosin may increase the hypotensive activities of Nimesulide.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nimesulide.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Nimesulide.
UrokinaseNimesulide may increase the anticoagulant activities of Urokinase.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Nimesulide.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nimesulide.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Nimesulide.
Vitamin EVitamin E may increase the antiplatelet activities of Nimesulide.
VorapaxarNimesulide may increase the anticoagulant activities of Vorapaxar.
VorapaxarVorapaxar may increase the antiplatelet activities of Nimesulide.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Nimesulide.
WarfarinNimesulide may increase the anticoagulant activities of Warfarin.
XimelagatranNimesulide may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Nimesulide.
Zoledronic acidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Rainsford KD: Nimesulide -- a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin. 2006 Jun;22(6):1161-70. [PubMed:16846549 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phospholipase a2 activity
Specific Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.
Gene Name:
PLA2G2E
Uniprot ID:
Q9NZK7
Molecular Weight:
15988.525 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.Lactotransferrin is a major iron-binding and multifunctional protein found in exocrine fluids such as breast milk and mucosal secretions. Has antimicrobial activity, which depends on the extracellular cation concentration. Antimicrobial properties incl...
Gene Name:
LTF
Uniprot ID:
P02788
Molecular Weight:
78181.225 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on September 11, 2007 11:49 / Updated on August 17, 2016 12:24